Caribou Biosciences Stock

cariboubio.comHealthcareFounded: 2011Funding to Date: $41.55MM

Caribou Biosciences is a leading clinical-stage CRISPR genome editing biotechnology company developing an internal pipeline of off-the-shelf, genome-edited CAR-T and natural killer (NK) cell therapies.

Register for Details

For more details on financing and valuation for Caribou Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Caribou Biosciences.

Register Today

Team

Management Team

Barbara McClung
Chief Legal Officer and Corporate Secretary
Timothy Herpin Ph.D
Chief Business Officer
Chris Fuller
Vice President, Informatics
Jennifer Doudna Ph.D
Co-Founder & Scientific Advisor
Steven Kanner Ph.D
Chief Scientific Officer
Edny Inui
Director, Business Development
James Berger
Co-Founder
Rachel Haurwitz Ph.D
Co-Founder, Board Member, President and Chief Executive Officer
Martin Jinek Ph.D
Co-Founder & Scientific Advisor
Scott Gradia Ph.D
Vice President of Platform Research

Board Members

Philip Austin
Anterra Capital
Robert Weisskoff Ph.D
Natalie Sacks MD
Rachel Haurwitz Ph.D

Other companies like Caribou Biosciences in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
 
 
Sector
Last Round Est. Valuation
$1.08B

News

Caribou Biosciences, Inc., a leading CRISPR genome editing company, announced the publication of a new study demonstrating human genome engineering wi